排序方式: 共有37条查询结果,搜索用时 0 毫秒
1.
紫杉醇联合顺铂治疗晚期食管癌的疗效观察 总被引:2,自引:1,他引:2
我们对临沂市肿瘤医院收治的48例晚期食管癌患者分别应用紫杉醇(Taxol)联合DDP(简称TP组)及DDP联合5FU(简称PF组)治疗,比较两组疗效,总结报道如下。1对象与方法1.1病例选择及一般资料2000年3月~2003年3月收治的48例患者均经病理确诊,并经临床体检、食管Χ线片、CT或B超等检查确诊为晚期食管癌。所有病例均系初治患者,年龄43~72岁,中位年龄61岁。Karno fasky评分≥60,预计生存期3个月以上,血常规及心、肝、肾功能正常。按随机数字表法分为TP组(23例)和PF组(25例),两组病例均衡性检验差异无统计学意义,具有可比性。1.2治疗方法TP… 相似文献
2.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
3.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
4.
目的:探究人表皮生长因子受体-2阳性乳腺癌患者采用曲妥珠单抗联合NP方案治疗对其疾病控制率及血清T淋巴细胞亚群水平的影响。方法:选取2016年9月~2018年9月收治的人表皮生长因子受体-2阳性乳腺癌患者42例,根据治疗方案不同分为观察组和对照组各21例。对照组采用NP方案(长春瑞滨+顺铂)治疗,观察组采用曲妥珠单抗联合NP方案治疗。比较两组治疗总有效率、疾病控制率、血清T淋巴细胞亚群(CD3~+、CD4~+、CD8~+)水平。结果:两组治疗总有效率、疾病控制率比较,差异均无统计学意义(P0.05);观察组治疗后CD3~+、CD4~+水平高于对照组,CD8~+水平低于对照组(P0.05)。结论:曲妥珠单抗联合NP方案治疗人表皮生长因子受体-2阳性乳腺癌,可有效调节患者血清T淋巴细胞亚群水平,增强机体免疫力。 相似文献
5.
目的观察血钙水平变化对提示肺癌骨转移的临床意义。方法用生化分光光度法测定肺癌骨转移患者27例、肺癌非骨转移患者45例、常规体检的正常者45例清晨空腹静脉血的血清钙、游离钙水平。结果肺癌伴骨转移组患者血清钙、游离钙水平明显高于肺癌未伴骨转移组、正常对照组,差异均有统计学意义(P均<0.05);肺癌未伴骨转移组和正常对照组患者血清钙、游离钙水平比较差异均无统计学意义(P均>0.05)。结论肺癌患者血清钙、游离钙可以作为早期诊断肺癌骨转移的较有价值的生化指标。 相似文献
6.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
7.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
8.
1975年 5月至 1985年 5月 ,我们共收治垂体瘤放射治疗病人 10 6例。本文总结其中资料完整的 84例进行分析 ,以首次治疗方式分为单纯放疗组 (简称单放组 )共 4 2例 ,经额入路手术后放疗组 (简称综合组 ) 42例 ,全部病例已随访 10年以上。许多文献报告由于垂体瘤位置特殊 ,常侵蚀邻近组织 ,手术难以切净 ,采用术后配合放射治疗 ,以减少肿瘤的复发[1,2 ] ,现将放射治疗在垂体瘤治疗中的作用及放射剂量与生存的关系分析如下 :材料和方法84例中男 5 0例 ,女 34例 ,男女比为 1.5∶1;年龄 9~ 5 6岁 ,其中 9~ 2 9岁 14例 ,占 16 .7% ,30~ 4 5岁 6… 相似文献
9.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
10.
[目的]探讨紫杉醇脂质体和紫杉醇对胃癌细胞系BGC-823增殖状况和侵袭能力影响。[方法]用紫杉醇脂质体和紫杉醇处理人胃癌BGC-823细胞,倒置显微镜下观察细胞形态变化,MTT绘制细胞生长曲线,TUNEL检测细胞凋亡,细胞划痕法和Transwell检测胃癌细胞的侵袭力。[结果]用紫杉醇脂质体和紫杉醇处理胃癌BGC-823细胞后,细胞的增殖能力和体外侵袭能力明显减弱,凋亡率增加,但两者之间相比无显著性差异(P〉0.051。[结论]紫杉醇脂质体具有和紫杉醇相似的抑制胃癌BGC-823细胞增殖和侵袭的能力。 相似文献